ReviewTrends in pharmacological sciences2007
Viruses as anticancer drugs.
Review in Trends in pharmacological sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed.
- Measles virus for cancer therapy.Current topics in microbiology and immunology · 2009Trial
- Global research trends in oncolytic virotherapy for sarcomas of bone and soft tissue (2000-2024): a bibliometric and visualization study.Translational cancer research · 2026Article
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression.Cancer immunology, immunotherapy : CII · 2025Article
- Experimental models for developing oncolytic virotherapy for metastatic prostate cancer.Frontiers in immunology · 2025Review
- Exosome-based immunotherapy as an innovative therapeutic approach in melanoma.Cell communication and signaling : CCS · 2024Review
- Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.Molecular therapy. Oncology · 2024Review
- Article
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.Scientific reports · 2023Article
- Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.Frontiers in pharmacology · 2023Article
- Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.Biomedicines · 2022Review
- In Vivo Targeting of the Neurovascular Unit: Challenges and Advancements.Cellular and molecular neurobiology · 2022Review
- Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.Frontiers in immunology · 2022Review
- Oncolytic viruses for triple negative breast cancer and beyond.Biomarker research · 2021Review
- Current strategies in engaging oncolytic viruses with antitumor immunity.Molecular therapy oncolytics · 2021Review
- Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review.Future science OA · 2021Review
- Applications of nuclear-based imaging in gene and cell therapy: probe considerations.Molecular therapy oncolytics · 2021Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue is the key to safety, and this goal can be achieved through a variety of ingenious virus-engineering strategies. Antiviral immunity remains a significant barrier to the clinical efficacy of oncolytic viruses but this is being addressed by using novel immune-evasive delivery strategies and immunosuppressive drugs. Noninvasive pharmacokinetic monitoring is facilitated by engineering marker genes into the viral genome. Clinical data on the pharmacokinetics of oncolytic viruses will be the key to accelerating their development and approval as effective anticancer drugs. This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.